Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma
The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab
Tiffany Richards, PhD, ANP-BC, and the rest of the panel offer clinical advice on the care of patients with multiple myeloma who are receiving talquetamab.
The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
Managing Talquetamab-Associated Toxicities in Patients with MM
Comprehensive insights on the management of toxicities seen in patients with multiple myeloma who are receiving talquetamab.
Educating Patients on Adverse Effects Related to Talquetamab in MM
Expert perspectives on educating patients with multiple myeloma on adverse effects related to treatment with talquetamab.
Treatment Sequencing and the Role of Talquetamab in MM
Clinical insights on treatment sequencing and the role of talquetamab, highlighting its safety profile in patients with multiple myeloma.
Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM
Turning the focus back to the clinical scenario, Donna Catamero, ANP-BC, OCN, CCRC, discusses the patient’s repeat diagnostic workup and the panel provides their insights on treatment decisions.
Resources for Educating Patients with Myeloma
Focusing on patient education, the panel outlines resources available to help patients with multiple myeloma navigate their treatment journey.
Patient Scenario: A 63-Year-Old Man with Multiple Myeloma
A panel of experts on multiple myeloma review a patient profile, offer their initial impressions, and highlight the role of an advanced practice provider.
Clinical Practice Perspectives on Treatment of MM with Bispecifics
Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.
Selecting and Sequencing Bispecifics and CAR-T Therapies in R/R MM
A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.
Patient Case 3: Relapsed/Refractory Multiple Myeloma
Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.
Treatment Strategies for Patients With Transplant-Ineligible NDMM
Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.
Patient Case 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.
Optimal Selection of Therapy for Patients With Transplant-Eligible NDMM
A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.
